The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial [0.03%]
原发性胆汁性胆管炎和胆汁淤积性瘙痒患者中林西瑞普的三期随机、多中心、双盲、安慰剂对照试验（GLISTEN）
Gideon M Hirschfield,Christopher L Bowlus,David E J Jones et al.
Gideon M Hirschfield et al.
Background: Cholestatic pruritus is common and undertreated in primary biliary cholangitis (PBC) and negatively affects patients' lives. We aimed to evaluate the safety and efficacy of linerixibat, an ileal bile acid tran...
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial [0.03%]
非肝硬化原发性硬化性胆管炎患者中的cilofexor（PRIMIS）：一项随机、双盲、多中心、安慰剂对照的III期临床试验
Michael Trauner,Cynthia Levy,Atsushi Tanaka et al.
Michael Trauner et al.
Background: There is currently no pharmacological therapy proven to alter the natural course of primary sclerosing cholangitis (PSC). The PRIMIS trial evaluated the efficacy and harms of the farnesoid X-activated receptor...
Elisabeth Eggermont,Krisztina Gecse,Noa Krugliak Cleveland et al.
Elisabeth Eggermont et al.
Ulcerative colitis has traditionally been regarded as a non-fibrotic, solely mucosal disease, whereas Crohn's disease is characterised by transmural inflammation and fibrosis. However, more recent evidence supports the existence of disease ...
Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis [0.03%]
原发性胆汁性胆管炎瘙痒的回肠胆汁酸输运抑制剂疗法
Ansgar W Lohse,David N Assis
Ansgar W Lohse
Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced? [0.03%]
克罗恩病的治疗优化：主要是在早期与晚期之间，还是在生物制剂初治与经治之间？
Marte Lie Høivik
Marte Lie Høivik
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study [0.03%]
vedolizumab治疗早期及晚期克罗恩病（LOVE-CD）：一项4期开放标记队列研究
Geert R D&#x;Haens,Mark Löwenberg,Filip Baert et al.
Geert R D&#x;Haens et al.
Background: Vedolizumab is efficacious in inducing and maintaining clinical remission in Crohn's disease. However, prospective data about its efficacy in early Crohn's disease are scarce. We aimed to evaluate the ability ...
Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial [0.03%]
电视胸腔镜手术与开放食管切除术治疗食管癌患者的疗效：一项多中心、开放标签、随机对照III期非劣效性研究（JCOG1409 MONET）
Hiroya Takeuchi,Ryunosuke Machida,Masahiko Ando et al.
Hiroya Takeuchi et al.
Background: Thoracoscopic oesophagectomy, a minimally invasive treatment for oesophageal cancer, is used worldwide. However, no large-scale, multicentre, randomised controlled trial has compared long-term survival as the ...
Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases [0.03%]
原发性胆汁性胆管炎患者的疲劳感：来自欧洲罕见肝病参考网络的立场文件
Ozgur M Koc,Anne-Kristin Toussaint,Aurelie Untas et al.
Ozgur M Koc et al.
Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence relating to fatigue in PBC to provide guidanc...